Tresiba® reduces hypoglycaemia regardless of blood sugar

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
88
Tresiba® reduces hypoglycaemia regardless of blood sugar level

Abu Dhabi, UAE, 7 December 2017 - People with either type 1 or type 2 diabetes treated with Tresiba ® had fewer episodes of low blood sugar (hypoglycaemia) compared with people on insulin glargine U100 regardless of whether they had achieved blood sugar targets. 1 These new post-hoc analyses from the SWITCH 1 and 2 trials were presented at the International Diabetes Federation (IDF) Annual Congress in Abu Dhabi today. 2,3

"Achieving target blood sugar levels can be a constant challenge for people with diabetes treated with insulin, and this is made even more complex by the risk of hypoglycaemia," said Mads Krogsgaard Thomsen, executive vice president and chief science officer at Novo Nordisk. "Tresiba ® has consistently been shown to provide stable blood sugar control while at the same time reducing hypoglycaemia compared with insulin glargine U100; it is very encouraging to see that treatment with Tresiba ® helps people to achieve blood sugar control with fewer episodes of hypoglycaemia regardless of their blood sugar levels in this analysis."

The findings of these analyses are consistent with the results of the main SWITCH trials which demonstrated significantly lower rates of overall symptomatic hypoglycaemia versus insulin glargine U100 in people with type 1 and type 2 diabetes. 2 , 3

About hypoglycaemia Hypoglycaemia occurs when blood sugar levels are too low and cannot provide the body's organs with the energy they need. Hypoglycaemia can cause a range of symptoms including confusion, trembling, sweating, increased heart rate, difficulty with concentration and/or speech and in severe cases can lead to a seizure or coma. 4-6 Severe hypoglycaemia can cause extensive damage to the body and is significantly associated with cardiovascular death. 7 Every month, 46.5% of people with type 2 diabetes and 83.0% of people with type 1 diabetes experience a hypoglycaemic episode. 8

About the new analyses The analyses, based on the recent SWITCH trials, separated people into two groups depending on whether they had achieved target blood sugar levels (defined as HbA 1c of 7.0% or less) during the maintenance period of the trial. 1 Target blood sugar levels are those recommended by the joint guidelines of the American Diabetes Association and the European Association for the Study of Diabetes. 9

About SWITCH 1 and 2 SWITCH 1 and SWITCH 2 were two phase 3b, 64-week, double-blind, randomised, treat-to-target, 2-period crossover trials that investigated the hypoglycaemia profile of Tresiba ® compared with insulin glargine U100 in people with type 1 and type 2 diabetes, respectively. The trial design included a titration period in which the doses of study treatments (Tresiba ® or insulin degludec U100) were gradually increased over a 16 week period, followed by a 16 week maintenance period during which a constant dose of study treatment was maintained. 2 , 3 The primary endpoint was the number of severe or blood glucose-confirmed symptomatic hypoglycaemic episodes observed in participants during the maintenance period. 2 , 3

About Tresiba ®

Tresiba ® (insulin degludec) is a once-daily basal insulin that provides a duration of action beyond 42 hours with a flat and stable glucose-lowering effect. 10 , 11 It has been shown to provide a lower risk of overall, nocturnal and severe hypoglycaemia, and low variability in blood glucose levels versus insulin glargine U100. 11 , 12 Tresiba ® received its first regulatory approval in September 2012 and has since been approved in more than 80 countries globally. It is now commercially available in more than 50 countries.

Further information

Media:    
Katrine Sperling +45 4442 6718 krsp@novonordisk.com
Åsa Josefsson +45 3079 7708 aajf@novonordisk.com
     
Investors :    
Peter Hugreffe Ankersen +45 3075 9085 phak@novonordisk.com
Hanna Ögren +45 3079 8519 haoe@novonordisk.com
Anders Mikkelsen +45 3079 4461 armk@novonordisk.com
Christina Kjær +45 3079 3009 cnje@novonordisk.com
Kasper Veje (US) +1 609 235 8567 kpvj@novonordisk.com

References 1.         Gumprecht J, Lane W, Chaykin LB , et al. Lower rate of hypoglycaemia with insulin degludec vs. insulin glargine U100 after adjusting for HbA1c in SWITCH 1 and 2. Poster presentation. International Diabetes Federation (IDF) Annual Congress 2017, Abu Dhabi, UAE. December 2017. 2.         Lane W, Bailey TS, Gerety G , et al. Effect of insulin degludec vs insulin glargine U100 on hypoglycemia in patients with type 1 diabetes: The SWITCH 1 randomized clinical trial. JAMA . 2017;318:33-44. 3.         Wysham C, Bhargava A, Chaykin L , et al. Effect of insulin degludec vs insulin glargine U100 on hypoglycemia in patients with type 2 diabetes: The SWITCH 2 randomized clinical trial. JAMA . 2017;318:45-56. 4.         Seaquist ER, Anderson J, Childs B , et al. Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society. Diabetes Care . 2013;36:1384-1395. 5.         International Hypoglycaemia Study Group. Diagnosis of hypoglycaemia. Available online at http://ihsgonline.com/understanding-hypoglycaemia/diagnosis . Last accessed November 2017. 6.         Cryer P. Hypoglycemia, functional brain failure, and brain death. Journal of Clinical Investigation . 2007;117:868-870. 7.         Pieber TR, Marso SP, McGuire DK , et al. DEVOTE 3: temporal relationships between severe hypoglycaemia, cardiovascular outcomes and mortality. Diabetologia . 2017. 8.         Khunti K, Alsifri S, Aronson R , et al. Rates and predictors of hypoglycaemia in 27 585 people from 24 countries with insulin-treated type 1 and type 2 diabetes: the global HAT study. Diabetes Obes Metab . 2016;18:907-915. 9.         Inzucchi SE, Bergenstal RM, Buse JB , et al. Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient Centered Approach. Diabetes Care 2015;38:140-149. 10.       Haahr H, Heise T. A review of the pharmacological properties of insulin degludec and their clinical relevance. Clin Pharmacokinet . 2014;53:787-800. 11.       EMA. Tresiba ® Summary of Product Characteristics. Available at: http://www.ema.europa.eu/docs/en_GB/document_...138940.pdf . Last accessed: November 2017. 12.       Marso SP, McGuire DK, Zinman B , et al. Efficacy and safety of degludec versus glargine in type 2 diabetes. N Engl J Med . 2017;377:723-732.

Attachments:

http://www.globenewswire.com/NewsRoom/Attachm...b9c50cbc89

Scroll down for more posts ▼

Top 10 Most Recent News Articles

NextPatient’s KLAS Marks Signal Specialty Workflow Fit

Updated Category News Views 22

A 93.3 score in healthcare software deserves a second look. Not a victory lap, not a drumroll—just a serious look at whether the product is solving an annoying, expensive operational problem for specialty practices. NextPatient’s recognition in the 2026 KLAS Emerging Solutions Top 20 Report lands in that category. The company placed in the top five for improving...

Continue Reading
Bank of America AML Claims Put Controls Under Fire

Updated Category News Views 157

A $1.2 billion compliance bill has a way of making investors stop pretending controls are boring. Moore Law PLLC is urging Bank of America shareholders to contact the firm over allegations tied to the bank's anti-money-laundering and Bank Secrecy Act systems. The notice follows what it describes as landmark October 13, 2026 enforcement actions by the Treasury Department's...

Continue Reading
Azazie Tests Bridal Demand With Two East Coast Pop-Ups

Updated Category News Views 127

Wedding dresses are a miserable product to buy sight unseen, no matter how pretty the product photos look. That basic fact is why Azazie’s two East Coast pop-ups on November 21 and 22 deserve a closer look. This is not some grand retail rollout, and nobody should pretend a pair of short events rewrites the bridal market. But it is a practical test of where a...

Continue Reading
Seeking Alpha Premium Review: Data Meets Human Judgment

Updated Category News Views 64

A spreadsheet can spot a cracked windshield, but it cannot tell you where the truck is headed. That is the useful, slightly irritating truth behind Seeking Alpha Premium’s 2026 pitch: it puts an enormous amount of stock-research machinery in one place, yet the investor still has to do the driving. Software Experts has highlighted the service in its review of...

Continue Reading
Suntory Flowers Tests NASCAR as a Garden Retail Engine

Updated Category News Views 130

Orange sheet metal and flowering vines are an odd couple, which is precisely why this South Florida promotion has some bite. A plant marketer took a hard left turn Suntory Flowers put its Sun Parasol mandevillas alongside DGM Racing at Homestead-Miami Speedway, celebrating the millions of plants grown in South Florida. That is not a conventional horticulture play, and...

Continue Reading
COPD Support Program Targets a Costly Care Gap Today

Updated Category News Views 24

Breathing trouble gets shrugged off far too easily, and that casual mistake has consequences. World COPD Day puts chronic obstructive pulmonary disease back in view, with the American Lung Association emphasizing a free Lung Health Navigator program for people living with COPD, their caregivers and families. This is not flashy medicine or a miracle-cure pitch. It is...

Continue Reading
Paratus on the Move: Seagems JV Under the Microscope

Updated Category News Views 194

What's Cooking with Paratus Energy? Paratus Energy Services Ltd. (ticker: PLSV) just threw us a curveball, announcing a strategic review of its participation in the Seagems joint venture. Now, before you get too jazzed about ticker talk—hold your horses. No one's making any promises about transactions just yet. The decision's still hanging in the balance, even as they...

Continue Reading
Yatsen’s November 25 Report Is the Real Beauty Test

Updated Category News Views 0

Beauty shelves can hide a lot of sins, but earnings day tends to drag them into fluorescent light. Yatsen will release unaudited third-quarter 2026 financial results before the U.S. market opens on Wednesday, November 25, then management will take questions at 7:30 a.m. Eastern Time. For anyone following NYSE:YSG, this is not a results story yet. It is a calendar marker,...

Continue Reading
Utility Global’s India Steel Move Needs Hard Numbers

Updated Category News Views 104

Steel decarbonization announcements can sound enormous before a single bolt gets tightened. Utility Global says it plans to deploy its first industrial H2Gen project in India with Tata Steel, and that is plainly worth watching. Tata Steel is a serious industrial name, India is a consequential steel market, and any technology that can credibly lower emissions from heavy...

Continue Reading
Vector's Peptide Pact Needs Proof Before Any Payday

Updated Category News Views 78

A famous orthopedic name can open doors, but it cannot manufacture clinical evidence. That is the plain reality behind Vector Science and Therapeutics' new collaboration with the Andrews Research & Education Foundation. Dr. James Andrews carries enormous credibility in sports medicine, earned across more than five decades of work. For Vector, that association matters. For...

Continue Reading

Top 5 Most Recently Viewed Articles

Exploring Innovations in Cannabinoid Medicine at Avicanna's Symposium

Updated Category News Views 131

Avicanna's 5th Medical Symposium on Cannabinoid Medicine On June 6, a well-anticipated medical symposium will be hosted by Avicanna Inc., a prominent biopharmaceutical company dedicated to the innovative exploration of cannabinoid-based medicine. This exciting event, taking place at the MaRS Discovery District, aims to bring together healthcare practitioners and...

Continue Reading
Gordian's Exciting New Initiative for Public Facility Planning

Updated Category News Views 277

Gordian's New Sourcewell Contract Gordian, a well-known provider of data-driven solutions for various phases of the building lifecycle, has recently secured a significant contract with Sourcewell. This partnership will broaden Gordian’s offerings to numerous government and educational organizations eager to enhance their facility planning capabilities. Facilitating...

Continue Reading
Paramount Global CFO Transition: A New Era Begins

Updated Category News Views 251

Paramount Global Announces Significant Leadership Change Paramount Global (NASDAQ: PARA) has made a noteworthy announcement regarding its executive leadership. Naveen Chopra, who has been serving as the Chief Financial Officer and Executive Vice President, will be departing from the company to explore new opportunities. The company's Board of Directors has stated that...

Continue Reading
Explore the Potential of Axsome, CRISPR, and Pfizer Stocks

Updated Category News Views 134

Back in 2023, the stock market was a mixed bag, with plenty of sectors showing serious signs of overvaluation. You had legends like Warren Buffett sitting on a mountain of cash, clearly indicating he saw overpriced stocks everywhere. When seasoned investors hit the brakes on buying due to high valuations, it’s like an alarm bell for everyone else—caution was in the...

Continue Reading
Boeing's Production Delays and Its Impact on Suppliers

Updated Category News Views 245

A Closer Look at Boeing's Production Setbacks Boeing Co has recently notified its suppliers about a significant change to a key production milestone for its 737 MAX aircraft. This adjustment, which extends the timeline by six months, has raised concerns within the aviation industry. Sources indicate that the new objective is to achieve an output of 42 jets per month by...

Continue Reading